

ZIOPHARM ONCOLOGY INC  
Form 8-K  
November 17, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): November 17, 2016**

**ZIOPHARM Oncology, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**  
**of Incorporation)**

**001-33038**  
**(Commission**  
**File Number)**

**84-1475642**  
**(IRS Employer**  
**Identification No.)**

**One First Avenue, Parris Building 34, Navy Yard Plaza**

**Boston, Massachusetts**  
**(Address of Principal Executive Offices)**  
**(617) 259-1970**

**02129**  
**(Zip Code)**

**(Registrant's Telephone Number, including Area Code)**

**Not applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

**Item 7.01 Regulation FD Disclosure**

On November 17, 2016, ZIOPHARM Oncology, Inc., or the Company, will conduct an investor webcast summarizing clinical and nonclinical data from its multi-center Phase 1 study for its Ad-RTS-hIL-12 + orally-administered veledimex product candidate in patients with recurrent or progressive glioblastoma, or GBM, or Grade III malignant glioma, a form of brain cancer, presented at the 21<sup>st</sup> Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), being held November 17 – 20, 2016 in Scottsdale, Arizona. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K, including the information contained in the presentation furnished as Exhibit 99.2, is intended to be furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

**Item 8.01 Other Events**

On November 17, 2016, the Company issued a press release announcing its upcoming presentation of clinical and nonclinical data from its multi-center Phase 1 study for its Ad-RTS-hIL-12 + orally-administered veledimex product candidate in patients with recurrent or progressive GBM, or Grade III malignant glioma, a form of brain cancer, at the 21<sup>st</sup> Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), being held November 17 – 20, 2016 in Scottsdale, Arizona. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of the Company dated November 17, 2016
99.2	Presentation of the Company dated November 17, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

By: /s/ Kevin G. Lafond  
Name: Kevin G. Lafond  
Title: Vice President Finance, Chief Accounting  
Officer and Treasurer

Date: November 17, 2016

**INDEX OF EXHIBITS**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release of the Company dated November 17, 2016
99.2	Presentation of the Company dated November 17, 2016